Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of the worldwide prescription market.
Despite a slowdown in pricing, the report shows that the mean cost per patient per year still managed to hit $147,308 in 2017, more than four times the mean cost for non-orphan drugs at $30,708.
The mean price of the top 100 USA orphan drugs is expected to grow at an annual rate of 5.2%
Revlimid is forecasted to be the USA’s top selling orphan drug in 2024
Expected strong sales of Revlimid and Pomalyst will secure Celgene’s position as 2024 worldwide leader
Soliris generated the highest USA revenue per patient for orphan drugs in 2017
Lanadelumab is the most valuable orphan drug in R&D, with a Net Present Value of $7.48bn
